Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H8N4O2.H2O |
Molecular Weight | 198.1793 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CN1C2=C(N=CN2)C(=O)N(C)C1=O
InChI
InChIKey=INQSMEFCAIHTJG-UHFFFAOYSA-N
InChI=1S/C7H8N4O2.H2O/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;/h3H,1-2H3,(H,8,9);1H2
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C7H8N4O2 |
Molecular Weight | 180.164 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9676340 | https://www.ncbi.nlm.nih.gov/pubmed/27713276
Since its discovery as component of the tea leaf by Albert Kossel in 1888, the history of theophylline (CAS 58-55-9) has been a long and successful one. At the turn of the century, theophylline became less expensive due to chemical synthesis and was primarily used as diuretic in subsequent years. It was Samuel Hirsch who discovered the bronchospasmolytic effect of theophylline in 1992, however, despite this pioneering discovery theophylline continued to be used primarily as diuretic and cardiac remedy. The molecular mechanism of bronchodilatation is inhibition of phosphodiesterase(PDE)3 and PDE4, but the anti-inflammatory effect may be due to histone deacetylase (HDAC) activation, resulting in switching off of activated inflammatory genes.
Theophylline is indicated for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9676340
Curator's Comment: Albert Kossel discovered theophylline as a component of the tea leaf
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094125 |
|||
Target ID: CHEMBL2093863 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER Approved UseTheophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. Launch Date1982 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.51 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7332727/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
THEOPHYLLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg/mL steady, intravenous Highest studied dose Dose: 20 mg/mL Route: intravenous Route: steady Dose: 20 mg/mL Sources: Page: p.500 |
unhealthy, 39 years (51 % < 40 years) n = 87 Health Status: unhealthy Condition: COPD|asthma Age Group: 39 years (51 % < 40 years) Sex: M+F Population Size: 87 Sources: Page: p.500 |
Disc. AE: Vomiting... Other AEs: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (grade 3, 5.75%) Other AEs:Vomiting (12.64%) Sources: Page: p.500 |
1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Disc. AE: Gastrointestinal discomfort, Supraventricular tachycardia... Other AEs: Tremor, Nervousness... AEs leading to discontinuation/dose reduction: Gastrointestinal discomfort (grade 3, 16.7%) Other AEs:Supraventricular tachycardia (grade 3, 16.7%) Tremor (16.7%) Sources: Page: p.149Nervousness (16.7%) Dysrhythmias (grade 1, 16.7%) |
800 mg single, oral Recommended Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: Page: p.146 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M Population Size: 6 Sources: Page: p.146 |
|
800 mg 1 times / day steady, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: steady Dose: 800 mg, 1 times / day Sources: Page: p.148 |
unhealthy, 66 ± 9 n = 16 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 16 Sources: Page: p.148 |
|
1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Other AEs: Generalized epileptic seizure, Cardiac arrhythmias... Other AEs: Generalized epileptic seizure (grade 4-5) Sources: Cardiac arrhythmias (grade 4-5) Calcium increased serum Creatine kinase increased Blood myoglobin increased Leukocyte count increased Serum phosphate decreased Magnesium serum decreased Acute myocardial infarction Obstructive uropathy Cardio-respiratory arrest (grade 5) Hypoxic encephalopathy (grade 5) |
1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Other AEs: Vomiting, Abdominal pain... Other AEs: Vomiting (61%) Sources: Abdominal pain (12%) Diarrhea (14%) Hematemesis (2%) Hypokalemia (43%) Acid-base balance abnoraml (9%) Sinus tachycardia (62%) Supraventricular tachycardia (14%) Premature ventricular ectopic beats (19%) Hypotension (8%) Nervousness (21%) Tremor (14%) Disorientation (11%) Seizures (5%) |
1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Other AEs: Vomiting, Hypokalemia... Other AEs: Vomiting (30%) Sources: Hypokalemia (44%) Hyperglycemia (18%) Acid-base balance abnoraml (9%) Sinus tachycardia (100%) Supraventricular tachycardia (12%) Premature ventricular ectopic beats (10%) Atrial flutter/ fibrillation (12%) Multifocal atrial tachycardia (2%) Hemodynamic instability (40%) Tremor (16%) Seizures (14%) |
10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Other AEs: Abdominal pain, Rhabdomyolysis... Other AEs: Abdominal pain (21%) Sources: Rhabdomyolysis (7%) Hypotension (21%) Nervousness (64%) Disorientation (7%) |
10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Other AEs: Vomiting, Hypokalemia... Other AEs: Vomiting (73%) Sources: Hypokalemia (85%) Hyperglycemia (98%) Acid-base balance abnoraml (34%) Sinus tachycardia (100%) Supraventricular tachycardia (2%) Premature ventricular ectopic beats (3%) Atrial flutter/ fibrillation (1%) Hemodynamic instability (7%) Tremor (38%) Seizures (5%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vomiting | 12.64% | 20 mg/mL steady, intravenous Highest studied dose Dose: 20 mg/mL Route: intravenous Route: steady Dose: 20 mg/mL Sources: Page: p.500 |
unhealthy, 39 years (51 % < 40 years) n = 87 Health Status: unhealthy Condition: COPD|asthma Age Group: 39 years (51 % < 40 years) Sex: M+F Population Size: 87 Sources: Page: p.500 |
Vomiting | grade 3, 5.75% Disc. AE |
20 mg/mL steady, intravenous Highest studied dose Dose: 20 mg/mL Route: intravenous Route: steady Dose: 20 mg/mL Sources: Page: p.500 |
unhealthy, 39 years (51 % < 40 years) n = 87 Health Status: unhealthy Condition: COPD|asthma Age Group: 39 years (51 % < 40 years) Sex: M+F Population Size: 87 Sources: Page: p.500 |
Nervousness | 16.7% | 1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Tremor | 16.7% | 1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Dysrhythmias | grade 1, 16.7% | 1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Gastrointestinal discomfort | grade 3, 16.7% Disc. AE |
1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Supraventricular tachycardia | grade 3, 16.7% Disc. AE |
1200 mg 1 times / day steady, oral Recommended Dose: 1200 mg, 1 times / day Route: oral Route: steady Dose: 1200 mg, 1 times / day Sources: Page: p.149 |
unhealthy, 66 ± 9 n = 6 Health Status: unhealthy Condition: COPD Age Group: 66 ± 9 Sex: M+F Population Size: 6 Sources: Page: p.149 |
Acute myocardial infarction | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Blood myoglobin increased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Calcium increased serum | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Creatine kinase increased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Leukocyte count increased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Magnesium serum decreased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Obstructive uropathy | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Serum phosphate decreased | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
|
Cardiac arrhythmias | grade 4-5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Generalized epileptic seizure | grade 4-5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Cardio-respiratory arrest | grade 5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Hypoxic encephalopathy | grade 5 | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Sources: |
Disorientation | 11% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Abdominal pain | 12% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Diarrhea | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Supraventricular tachycardia | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Tremor | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Premature ventricular ectopic beats | 19% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Hematemesis | 2% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Nervousness | 21% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Hypokalemia | 43% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Seizures | 5% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Vomiting | 61% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Sinus tachycardia | 62% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Hypotension | 8% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Acid-base balance abnoraml | 9% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 102 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 102 Sources: |
Premature ventricular ectopic beats | 10% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Sinus tachycardia | 100% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Atrial flutter/ fibrillation | 12% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Supraventricular tachycardia | 12% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Seizures | 14% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Tremor | 16% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Hyperglycemia | 18% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Multifocal atrial tachycardia | 2% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Vomiting | 30% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Hemodynamic instability | 40% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Hypokalemia | 44% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Acid-base balance abnoraml | 9% | 1600 mg 1 times / day multiple, oral (max) Overdose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
unhealthy n = 92 Health Status: unhealthy Condition: asthma|emphysema|chronic bronchitis Population Size: 92 Sources: |
Abdominal pain | 21% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Hypotension | 21% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Nervousness | 64% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Disorientation | 7% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Rhabdomyolysis | 7% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 14 Health Status: unknown Population Size: 14 Sources: |
Atrial flutter/ fibrillation | 1% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Sinus tachycardia | 100% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Supraventricular tachycardia | 2% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Premature ventricular ectopic beats | 3% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Acid-base balance abnoraml | 34% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Tremor | 38% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Seizures | 5% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Hemodynamic instability | 7% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Vomiting | 73% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Hypokalemia | 85% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
Hyperglycemia | 98% | 10 mg/kg single, oral (min) Overdose Dose: 10 mg/kg Route: oral Route: single Dose: 10 mg/kg Sources: |
unknown n = 157 Health Status: unknown Population Size: 157 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[The effect of GM-CSF on endothelin-1 and endothelin converting enzyme gene expression in human airway smooth muscle cells with or without theophylline incubation]. | 1997 Oct |
|
Functional assay of NF-kappaB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline. | 1999 Apr |
|
Epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus. | 1999 Jul |
|
[A case of acute renal failure with rhabdomyolysis caused by the interaction of theophylline and clarithromycin]. | 1999 Jun |
|
Effects of Saiko-ka-ryukotsu-borei-to, a Japanese Kampo medicine, on tachycardia and central nervous system stimulation induced by theophylline in rats and mice. | 1999 Mar |
|
Gamma-aminobutyric acid and glutamic acid receptors may mediate theophylline-induced seizures in mice. | 1999 Mar |
|
Life-threatening events after theophylline overdose: a 10-year prospective analysis. | 1999 May 10 |
|
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. | 1999 Nov |
|
[A case of acute theophylline intoxication with repeated status convulsivus]. | 1999 Nov |
|
Theophylline as a therapy for chronic lymphocytic leukemia: a case report and review of literature. | 2000 |
|
Effects of theophylline on human eosinophil functions: comparative study with neutrophil functions. | 2000 Aug |
|
Steroid hormone activity of flavonoids and related compounds. | 2000 Jul |
|
Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice. | 2000 Oct |
|
Oral methyl-xanthines for bronchiectasis. | 2001 |
|
Methyl-xanthines for exacerbations of chronic obstructive pulmonary disease. | 2001 |
|
Treatment options for sleep apnoea. | 2001 |
|
A novel method for measuring gel strength of controlled release hydrogel tablets using a cone/plate rheometer. | 2001 |
|
Caffeine citrate: a review of its use in apnoea of prematurity. | 2001 |
|
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. | 2001 Apr |
|
Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. | 2001 Apr |
|
Caffeine metabolism before and after liver transplantation. | 2001 Feb |
|
Metabolism of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in human hepatocytes: 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid is a major detoxification pathway catalyzed by cytochrome P450 1A2. | 2001 Feb |
|
Myocardial perfusion imaging findings and the role of adenosine in the warm-up angina phenomenon. | 2001 Feb |
|
Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in vitro. | 2001 Feb |
|
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. | 2001 Feb |
|
Therapeutic options for the management of patients with cardiac syndrome X. | 2001 Feb |
|
Mechanism of prolonged vasorelaxation to ATP in the rat isolated mesenteric arterial bed. | 2001 Feb |
|
K(ATP)(+) channels, nitric oxide, and adenosine are not required for local metabolic coronary vasodilation. | 2001 Feb |
|
[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. | 2001 Feb 1 |
|
Screening of beta-2 agonists and confirmation of fenoterol, orciprenaline, reproterol and terbutaline with gas chromatography-mass spectrometry as tetrahydroisoquinoline derivatives. | 2001 Feb 10 |
|
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. | 2001 Feb 15 |
|
Hepatic arteriolo-portal venular shunting guarantees maintenance of nutritional microvascular supply in hepatic arterial buffer response of rat livers. | 2001 Feb 15 |
|
The calcium-dependent [3H]acetylcholine release from synaptosomes of brown trout (Salmo trutta) optic tectum is inhibited by adenosine A1 receptors: effects of enucleation on A1 receptor density and cholinergic markers. | 2001 Feb 16 |
|
[Cerebral infarction in a patient consuming MaHuang extract and guarana]. | 2001 Feb 3 |
|
[Theophylline in the treatment of sleep-related breathing disorders]. | 2001 Jan |
|
Development of heart failure in bradycardic sick sinus syndrome. | 2001 Jan |
|
Clinical correlations in infants in the neonatal intensive care unit with varying severity of gastroesophageal reflux. | 2001 Jan |
|
Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells. | 2001 Jan |
|
A novel transverse push-pull microprobe: in vitro characterization and in vivo demonstration of the enzymatic production of adenosine in the spinal cord dorsal horn. | 2001 Jan |
|
Suspected caffeine and ephedrine toxicosis resulting from ingestion of an herbal supplement containing guarana and ma huang in dogs: 47 cases (1997-1999). | 2001 Jan 15 |
|
Severe hyponatremia induced by theophylline and trimethoprim. | 2001 Jan 22 |
|
Mice with a deletion in the gene for CCAAT/enhancer-binding protein beta have an attenuated response to cAMP and impaired carbohydrate metabolism. | 2001 Jan 5 |
|
Newer and alternative non-steroidal treatments for asthmatic inflammation. | 2001 Jan-Feb |
|
Improvement of encapsulation efficiency of water-in-oil-in-water emulsion with hypertonic inner aqueous phase. | 2001 Jan-Feb |
|
Drug treatment of airway inflammation in asthma. | 2001 Mar |
|
Plasma adenosine levels and P-selectin expression on platelets in preeclampsia. | 2001 Mar |
|
Continuous venovenous haemofiltration for the treatment of theophylline toxicity. | 2001 Mar |
|
Profile of moxifloxacin drug interactions. | 2001 Mar 15 |
|
Inhibitory effect of theophylline on recombinant GABA(A) receptor. | 2001 Mar 5 |
|
Escape deficits induced by inescapable shock and metabolic stress are reversed by adenosine receptor antagonists. | 2001 May |
Patents
Sample Use Guides
For a given population there is no single theophylline dose that will provide both safe
and effective serum concentrations for all patients. The dose of theophylline must be individualized on the basis of serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk of adverse effects.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24231152
1 mM theophylline inhibited histamine release from human skin mast cells
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:57 GMT 2023
by
admin
on
Fri Dec 15 15:20:57 GMT 2023
|
Record UNII |
C137DTR5RG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C221
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
NDF-RT |
N0000175790
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-ATC |
R03DA74
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
DSLD |
3373 (Number of products:11)
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-ATC |
R03DA04
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
IARC | Theophylline | ||
|
WHO-ATC |
R03DB04
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
LIVERTOX |
NBK548479
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
CFR |
21 CFR 862.3880
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-VATC |
QR03DB04
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-ATC |
R03DA54
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-VATC |
QR03DA54
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-VATC |
QR03DA74
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
||
|
WHO-VATC |
QR03DA04
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C872
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
DTXSID40208361
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL190
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
1653004
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
2620
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
Theophylline
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
413
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
C137DTR5RG
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
100000076988
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
5967-84-0
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
DB00277
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
91268
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
10438
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
757346
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
THEOPHYLLINE
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
28177
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
D013806
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
SUB15516MIG
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
SUB15520MIG
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY | |||
|
C137DTR5RG
Created by
admin on Fri Dec 15 15:20:57 GMT 2023 , Edited by admin on Fri Dec 15 15:20:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |